Cancer immunotherapy: Car T Cell Technology

A type of treatment in which a patient’s T cells (a type of immune cell) are altered in the laboratory so they will bind to cancer cells and destroy them. Blood from a vein in the patient’s arm flows through a tube to an apheresis machine (not shown), which eliminates the white blood cells, including the T cells, and directs the rest of the blood back to the patient. Then, the gene for a special receptor named a chimeric antigen receptor (CAR) is introduced into the T cells in the laboratory. Millions of the CAR T cells are developed in the laboratory and then given to the patient by infusion. The CAR T cells are able to bind to an antigen on the cancer cells and destroy them.

 

  • CAR-T cell therapy in Acute Lymphoblastic Leukaemia
  • CAR-T cells therapy in Chronic Lymphocytic Leukaemia
  • CAR-T cell in Multiple Myeloma

Related Conference of Cancer immunotherapy: Car T Cell Technology

July 28-29, 2025

45th Euro Congress on Cancer Science & Therapy

Paris, France
October 20-21, 2025

21st International Conference on Cancer Research

Barcelona, Spain
October 22-23, 2025

35th Experts Meet On Cancer Research & Therapy

Paris, France
October 24-25, 2025

25th World Congress on Cancer and Diagnostics

Zurich, Switzerland
November 20-21, 2025

26th World Congress on Cancer Summit

Amsterdam, Netherlands
November 24-25, 2025

43rd World Cancer Conference

Barcelona, Spain
December 08-09, 2025

13th Euro Breast Cancer and Therapeutics

Aix-en-Provence, France
February 19-20, 2026

7th Cancer Diagnostics & Treatment Conference

Miami, USA
February 19-20, 2026

8th International Conference on Women Oncology

Miami, USA
March 23-24, 2026

16th World Congress on Breast Cancer Research & Therapies

Aix-en-Provence, France

Cancer immunotherapy: Car T Cell Technology Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in